Canada markets close in 1 hour 1 minute

Fagron NV (ARSUF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
18.590.00 (0.00%)
As of 01:04PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close18.59
Open18.59
Bid0.00 x 0
Ask0.00 x 0
Day's Range18.59 - 18.59
52 Week Range13.50 - 19.26
Volume290
Avg. Volume539
Market Cap1.373B
Beta (5Y Monthly)0.29
PE Ratio (TTM)17.70
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.27 (1.46%)
Ex-Dividend DateMay 15, 2023
1y Target EstN/A
  • GlobeNewswire

    Disclosure notification from Mawer Investment Management Ltd.

    Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 March 2024 – 6PM CET Disclosure notification from Mawer Investment Management Ltd. On 18 March 2024, Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Mawer Investment Management Ltd. that its shareholding crossed the 5% disclosure threshold as the result of the acquisition of voting securities or voting rights on 15 March 2024. N

  • GlobeNewswire

    Fagron publishes annual report 2023

    Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron publishes annual report 2023 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2023. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 13 May 2024. The annual report is available in the official Dutch version and in English translatio

  • GlobeNewswire

    Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023

    Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 15 February 2024 – 7AM CET Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023 Fagron, the leading global player in pharmaceutical compounding today publishes its full year results for the period ending 31 December 2023. Key Highlights Strong topline performance with 11.6% reported revenue growth (12.5% at CER) and 10.5% organic revenue growth at CER supported